Ⓐ
PeptiBrief
Evidence Library
drug_development_review · 2004

AOD-9604 Metabolic

Wilding J · Current Opinion in Investigational Drugs
lowPMID · 15134286Verified
View source
Plain-English summary

AOD-9604 entered obesity trials, but the available peer-reviewed record does not establish it as an effective approved weight-loss medicine.

Population
Obesity drug-development programme
Intervention
AOD-9604
Outcomes measured
Development status|Early clinical investigation
Key findings
AOD-9604 had reached phase II development, but peer-reviewed evidence remained limited.
Limitations
Brief development review with little detailed clinical outcome reporting and no basis for modern compounded-product claims.
Risk of bias
High for efficacy conclusions — narrative development summary rather than a full randomized trial report.
Citation
Wilding J (2004). AOD-9604 Metabolic. Current Opinion in Investigational Drugs
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.